The latest price target for Kiora Pharmaceuticals (NASDAQ:KPRX) was reported by HC Wainwright & Co. on November 12, 2024. The analyst firm set a price target for $10.00 expecting KPRX to rise to within 12 months (a possible 219.49% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Kiora Pharmaceuticals (NASDAQ:KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.

The last upgrade for Kiora Pharmaceuticals Inc happened on February 9, 2023 when Maxim Group raised their price target to $12. Maxim Group previously had a hold for Kiora Pharmaceuticals Inc.

The last downgrade for Kiora Pharmaceuticals Inc happened on August 15, 2022 when Maxim Group changed their price target from N/A to N/A for Kiora Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.

While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $10.00 to $10.00. The current price Kiora Pharmaceuticals (KPRX) is trading at is $3.13, which is out of the analyst’s predicted range.